Home / Publications / RuII and RuIII complexes with imidazole ligands containing (benzyloxy)pyridinone moiety

RuII and RuIII complexes with imidazole ligands containing (benzyloxy)pyridinone moiety

Anna Alekseevna Fateeva 1
Anna Alekseevna Fateeva
,  ,  , 
Olga Nikolaevna Kovaleva 2
Olga Nikolaevna Kovaleva
,  , 
10.1016/j.mencom.2022.03.011
Published 2022-03-06
Communication , Volume 32, Issue 2, 186-188
5
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Fateeva A. A. et al. RuII and RuIII complexes with imidazole ligands containing (benzyloxy)pyridinone moiety // Mendeleev Communications. 2022. Vol. 32. No. 2. pp. 186-188.
GOST all authors (up to 50) Copy
Fateeva A. A., Shutkov I. A., Mazur D. M., Kovaleva O. N., Milaeva E. R., Nazarov A. A. RuII and RuIII complexes with imidazole ligands containing (benzyloxy)pyridinone moiety // Mendeleev Communications. 2022. Vol. 32. No. 2. pp. 186-188.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2022.03.011
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2022.03.011
TI - RuII and RuIII complexes with imidazole ligands containing (benzyloxy)pyridinone moiety
T2 - Mendeleev Communications
AU - Fateeva, Anna Alekseevna
AU - Shutkov, Ilya Aleksandrovich
AU - Mazur, Dmitrii Mikhailovich
AU - Kovaleva, Olga Nikolaevna
AU - Milaeva, Elena Rudol'fovna
AU - Nazarov, Alexey Anatol'evich
PY - 2022
DA - 2022/03/06
PB - Mendeleev Communications
SP - 186-188
IS - 2
VL - 32
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Fateeva,
author = {Anna Alekseevna Fateeva and Ilya Aleksandrovich Shutkov and Dmitrii Mikhailovich Mazur and Olga Nikolaevna Kovaleva and Elena Rudol'fovna Milaeva and Alexey Anatol'evich Nazarov},
title = {RuII and RuIII complexes with imidazole ligands containing (benzyloxy)pyridinone moiety},
journal = {Mendeleev Communications},
year = {2022},
volume = {32},
publisher = {Mendeleev Communications},
month = {Mar},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2022.03.011},
number = {2},
pages = {186--188},
doi = {10.1016/j.mencom.2022.03.011}
}
MLA
Cite this
MLA Copy
Fateeva, Anna Alekseevna, et al. “RuII and RuIII complexes with imidazole ligands containing (benzyloxy)pyridinone moiety.” Mendeleev Communications, vol. 32, no. 2, Mar. 2022, pp. 186-188. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2022.03.011.

Keywords

antiproliferative activity
imidazoles
pyridinone
ruthenium compounds
stability

Abstract

Preparation of novel imidazole ligands containing 3-(benzyloxy)pyridinone moiety is described. The Ruiii and Ruii leader-compounds containing the above-mentioned ligands were synthesized by coordination of imidazole group. The stability of the obtained compounds was explored in buffer solution and in the presence of DMSO, respectively, and their antiproliferative activity was assessed.

References

1.
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony E.J., Bolitho E.M., Bridgewater H.E., Carter O.W., Donnelly J.M., Imberti C., Lant E.C., Lermyte F., Needham R.J., Palau M., Sadler P.J., Shi H., Wang F., Zhang W., Zhang Z., et. al.
Chemical Science, 2020
5.
Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?
Coverdale J., Laroiya-McCarron T., Romero-Canelón I.
Inorganics, 2019
6.
Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Galanski M., Arion V., Jakupec M., Keppler B.
Current Pharmaceutical Design, 2003
7.
10.1016/j.mencom.2022.03.011_b0035
Pieper
Metallopharmaceuticals I: DNA Interactions, 1999
8.
10.1016/j.mencom.2022.03.011_b0040
Sava
Anticancer Res., 1999
9.
The development of RAPTA compounds for the treatment of tumors
Murray B.S., Babak M.V., Hartinger C.G., Dyson P.J.
Coordination Chemistry Reviews, 2016
10.
Metal-based antitumour drugs in the post genomic era.
Dyson P.J., Sava G.
Dalton Transactions, 2006
11.
10.1016/j.mencom.2022.03.011_b0055
Alessio
Molecules, 1995
13.
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota S., Rodrigues D.A., Crans D.C., Barreiro E.J.
Journal of Medicinal Chemistry, 2018
14.
Interaction of the NAMI-A complex with nitric oxide under physiological conditions
Oszajca M., Kuliś E., Stochel G., Brindell M.
New Journal of Chemistry, 2014
15.
Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity
Nowak-Sliwinska P., van Beijnum J.R., Casini A., Nazarov A.A., Wagnières G., van den Bergh H., Dyson P.J., Griffioen A.W.
Journal of Medicinal Chemistry, 2011
17.
Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death.
Nazarov A.A., Gardini D., Baquié M., Juillerat-Jeanneret L., Serkova T.P., Shevtsova E.P., Scopelliti R., Dyson P.J.
Dalton Transactions, 2013
18.
New highly cytotoxic organic and organometallic bexarotene derivatives
Nosova Y.N., Karlov D.S., Pisarev S.A., Shutkov I.A., Palyulin V.A., Baquié M., Milaeva E.R., Dyson P.J., Nazarov A.A.
Journal of Organometallic Chemistry, 2017
19.
Pyrone derivatives and metals: From natural products to metal-based drugs
Kandioller W., Kurzwernhart A., Hanif M., Meier S.M., Henke H., Keppler B.K., Hartinger C.G.
Journal of Organometallic Chemistry, 2011
20.
From Pyrone to Thiopyrone Ligands−Rendering Maltol-Derived Ruthenium(II)−Arene Complexes That Are Anticancer Active in Vitro
Kandioller W., Hartinger C.G., Nazarov A.A., Kuznetsov M.L., John R.O., Bartel C., Jakupec M.A., Arion V.B., Keppler B.K.
Organometallics, 2009
21.
Toxicity studies with ethyl maltol
GRALLA E.
Toxicology and Applied Pharmacology, 1969
23.
10.1016/j.mencom.2022.03.011_b0115
Ichimoto
Agric. Biol. Chem., 1970
24.
10.1016/j.mencom.2022.03.011_b0120
Yasumoto
Anticancer Res., 2004
27.
Basic 3-hydroxypyridin-4-ones: Potential antimalarial agents
Dehkordi L.S., Liu Z.D., Hider R.C.
European Journal of Medicinal Chemistry, 2008
28.
Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity
Mendoza-Ferri M.G., Hartinger C.G., Mendoza M.A., Groessl M., Egger A.E., Eichinger R.E., Mangrum J.B., Farrell N.P., Maruszak M., Bednarski P.J., Klein F., Jakupec M.A., Nazarov A.A., Severin K., Keppler B.K., et. al.
Journal of Medicinal Chemistry, 2009
29.
Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the in Vitro Antitumor Activity of Polynuclear Organometallic Compounds
Mendoza-Ferri M.G., Hartinger C.G., Nazarov A.A., Eichinger R.E., Jakupec M.A., Severin K., Keppler B.K.
Organometallics, 2009
30.
Is the Reactivity of M(II)−Arene Complexes of 3-Hydroxy-2(1H)-pyridones to Biomolecules the Anticancer Activity Determining Parameter?
Hanif M., Henke H., Meier S.M., Martic S., Labib M., Kandioller W., Jakupec M.A., Arion V.B., Kraatz H., Keppler B.K., Hartinger C.G.
Inorganic Chemistry, 2010
31.
Understanding the interactions of diruthenium anticancer agents with amino acids
Nazarov A.A., Mendoza-Ferri M., Hanif M., Keppler B.K., Dyson P.J., Hartinger C.G.
Journal of Biological Inorganic Chemistry, 2018
32.
Design, Synthesis, Physicochemical Properties, and Evaluation of Novel Iron Chelators with Fluorescent Sensors
Ma Y., Luo W., Quinn P.J., Liu Z., Hider R.C.
Journal of Medicinal Chemistry, 2004